DNA logo

GINKGO BIOWORKS HOLDINGS INC

DNANYSE
πŸ† #2466 by market capEarnings Nov 5US Equity
$12.74β–Ό $0.60 (βˆ’4.53%)
Pre-market Β· at close
πŸ””
Track DNA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.5%
7dβ–² 27.7%
14dβ–² 23.9%
30dβ–Ό 0.6%
ytdβ–² 53.3%
1yβ–² 6.0%
🏦Market Cap
$820M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-51.5%
Declining
πŸ“ŠGross Margin
77.7%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
6.8x
Fair
Otter Score
52
Fair

Trading Snapshot

Day Range
$12.72 – $13.94
52-Week Range
$5.37 – $18.22
Volume (shares)
153,214
Avg Volume (shares)
β€”
Shares Outstanding
64.3M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$170M
Last Q Revenue
$20M
P/E Ratio
β€”
P/S Ratio
6.8x
EPS (TTM)
$-5.00
Dividend Yield
β€”
Dilution (1yr)
+6.9%
DNA logo

GINKGO BIOWORKS HOLDINGS INC

DNA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$170Mβ–Ό βˆ’25.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
81.5%β–Ό βˆ’1.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$315Mβ–Ό βˆ’43.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$179Mβ–Ό βˆ’53.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
55.5Mβ–² +6.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$273Mβ–Ό βˆ’$367M YoY
StockOtter Β· stockotter.space

About GINKGO BIOWORKS HOLDINGS INC

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
52/100

Analyst Ratings

β“˜
Consensus
Sell
10 analysts
Strong Buy0
Buy0
Hold3
Sell4
Strong Sell3
Ratings as of Oct 2026

Latest News & Updates

News unavailable.